Last updated: August 28, 2026
FLOXIN IN DEXTROSE 5% was an intravenous ofloxacin product supplied in 5% dextrose for hospital use. Its commercial value has largely disappeared in the United States because the product is no longer an active growth brand, its regulatory exclusivity has expired, and intravenous fluoroquinolone demand shifted toward ciprofloxacin and levofloxacin. Public filings do not disclose product-level revenue, but the available regulatory record supports a conclusion of historical, not current, commercial relevance.
What is FLOXIN IN DEXTROSE 5%?
FLOXIN IN DEXTROSE 5% is an intravenous formulation of ofloxacin, a racemic fluoroquinolone antibacterial. The product was supplied as a ready-to-use solution in 5% dextrose, avoiding the need for hospital pharmacy dilution before administration.
| Attribute |
Product detail |
| Brand |
FLOXIN I.V. / FLOXIN IN DEXTROSE 5% |
| Active ingredient |
Ofloxacin |
| Drug class |
Fluoroquinolone antibacterial |
| Route |
Intravenous infusion |
| Diluent |
5% dextrose |
| Primary setting |
Hospital and institutional care |
| Original commercial sponsor |
Ortho-McNeil, associated with Johnson & Johnson |
| FDA status |
Historical product; no meaningful current branded market |
| Current strategic position |
Legacy product with limited or no U.S. commercial contribution |
The formulation was intended for patients requiring parenteral antibacterial therapy or those unable to take oral medication. Ofloxacin has high oral bioavailability, which limited the long-term value of maintaining a separate intravenous brand once patients could be switched to oral treatment.
What was the clinical and commercial role of ofloxacin injection?
Ofloxacin injection competed in a market where hospitals valued broad-spectrum Gram-negative coverage, convenient dosing, and the ability to transition patients from intravenous to oral therapy. Its principal commercial limitation was that oral ofloxacin provided a relatively efficient step-down option.
The product was used for infections involving the urinary tract, respiratory tract, skin and skin structures, pelvic organs, and other susceptible bacterial sites. Fluoroquinolone use was later constrained by resistance, safety warnings, antimicrobial stewardship programs, and competition within the class.
The U.S. market increasingly favored:
- Ciprofloxacin for selected Gram-negative and complicated urinary or gastrointestinal infections.
- Levofloxacin for respiratory and urinary indications.
- Generic fluoroquinolones supplied through hospital contracts.
- Non-fluoroquinolone alternatives where safety, resistance, or stewardship policies made them preferable.
FDA safety communications and labeling changes relating to tendon injury, peripheral neuropathy, central nervous system effects, dysglycemia, QT prolongation, aortic complications, and other risks reduced the attractiveness of fluoroquinolones for some routine uses [1][2].
When did FLOXIN IN DEXTROSE 5% lose exclusivity?
FLOXIN IN DEXTROSE 5% no longer has meaningful U.S. regulatory exclusivity. Its commercial protection was based mainly on the original product approval, brand recognition, manufacturing capability, and hospital contracting rather than an active patent moat.
| Protection category |
Current assessment |
| New chemical entity exclusivity |
Expired |
| Orphan exclusivity |
Not applicable |
| Pediatric exclusivity |
No current relevance |
| Active branded exclusivity |
Expired |
| Active Orange Book patent protection |
No material current protection identified for the legacy product |
| Biosimilar exclusivity |
Not applicable |
| Commercial differentiation |
Low |
Ofloxacin was approved in the United States decades ago. Any original composition, use, or formulation patents would have expired well before the current period. The product therefore lacks the type of patent-protected lifecycle that supports premium pricing for newer medicines.
What patents protect FLOXIN IN DEXTROSE 5%?
No active, commercially meaningful patent estate is associated with the legacy U.S. product based on the product’s age and the absence of a current branded market. The relevant intellectual-property categories were historically:
- Ofloxacin composition patents.
- Pharmaceutical formulation patents.
- Intravenous solution and container technology.
- Method-of-use patents for antibacterial treatment.
- Manufacturing and quality-control know-how.
These categories do not create a current barrier comparable with an active small-molecule patent estate. A 5% dextrose intravenous solution is technically reproducible by qualified manufacturers, subject to FDA approval, current good manufacturing practice, container-closure requirements, sterility controls, and stability validation.
The patent risk is therefore low for commercial entry, while regulatory and manufacturing execution remain the more important barriers.
What is the Orange Book status of FLOXIN IN DEXTROSE 5%?
The product is not commercially positioned as an active, protected reference brand. The FDA Orange Book is relevant to approved drug products and listed patents, but an old discontinued branded product does not retain practical market power merely because its historical NDA remains in the regulatory record [3].
For a generic applicant, the important questions would be:
- Whether the relevant reference product remains eligible for an abbreviated new drug application pathway.
- Whether an active reference listing exists for the specific intravenous presentation.
- Whether the applicant must rely on a suitability petition, 505(b)(2) application, or another pathway.
- Whether the proposed product is pharmaceutically equivalent in strength, route, dosage form, and container presentation.
- Whether the proposed product can satisfy sterility, particulate, extractables, leachables, and stability requirements.
Because intravenous ofloxacin is an old product with limited current U.S. commercial presence, the primary uncertainty is regulatory pathway and market size, not patent infringement.
Are there Paragraph IV challenges involving FLOXIN IN DEXTROSE 5%?
No material, current Paragraph IV litigation involving FLOXIN IN DEXTROSE 5% is publicly associated with the product. That result is commercially logical. Paragraph IV litigation is generally economically attractive when a branded product has substantial remaining sales and a valuable patent expiry date. A legacy ofloxacin infusion product does not offer that incentive.
A potential generic applicant would be more likely to pursue an ordinary abbreviated pathway or another regulatory route without a high-value patent challenge. The expected litigation burden is low, but the expected market opportunity is also low.
How strong is the patent estate for FLOXIN IN DEXTROSE 5%?
The patent estate is weak from a current commercial perspective.
| Factor |
Assessment |
| Composition patent life |
Expired |
| Formulation protection |
No current strategic significance identified |
| Method-of-use protection |
Expired or commercially immaterial |
| Manufacturing protection |
Potentially relevant as trade know-how, not a market-blocking patent |
| Design-around difficulty |
Low |
| Patent litigation exposure |
Low |
| Exclusivity value |
Negligible |
A manufacturer could face quality and regulatory risks without facing meaningful patent risk. For sterile injectable products, the practical barrier is often the cost and reliability of manufacturing rather than the ability to design around patents.
What is the FDA regulatory status of FLOXIN IN DEXTROSE 5%?
The product is a historical FDA-approved intravenous ofloxacin presentation. Its commercial status should be distinguished from safety-related withdrawal.
A discontinuation from commercial sale does not automatically mean that FDA determined the product was unsafe or ineffective. Legacy hospital products can disappear because of low demand, generic erosion, manufacturing economics, portfolio rationalization, supply-chain constraints, or substitution by newer products.
The product’s clinical risk profile became less favorable as FDA strengthened class-wide fluoroquinolone warnings. FDA advised that systemic fluoroquinolones should generally be reserved for certain situations when alternative therapies are available, particularly for uncomplicated infections where the risk-benefit profile is less favorable [1][2].
What formulations are protected by FLOXIN patents?
The product’s formulation was a sterile ofloxacin solution in 5% dextrose. Its commercial differentiation came from presentation and hospital usability, not a durable formulation platform.
Relevant technical attributes included:
- Premixed intravenous solution.
- Single-use infusion container.
- Controlled ofloxacin concentration.
- Compatibility with intravenous administration.
- Sterility and particulate control.
- Defined storage and in-use handling conditions.
These attributes can create regulatory and manufacturing complexity. They do not necessarily create enforceable patent exclusivity after the expiration of historical formulation patents.
How does FLOXIN IN DEXTROSE 5% compare with competing fluoroquinolones?
| Product |
Active ingredient |
Commercial position |
Key competitive advantage |
| FLOXIN IN DEXTROSE 5% |
Ofloxacin |
Legacy/discontinued branded product |
Oral-to-IV continuity and historical brand recognition |
| Cipro I.V. |
Ciprofloxacin |
Established hospital product with generic competition |
Strong Gram-negative positioning |
| Levaquin injection |
Levofloxacin |
Historically stronger respiratory positioning |
Broad hospital familiarity and convenient dosing |
| Generic ciprofloxacin injection |
Ciprofloxacin |
Price-driven institutional market |
Contracting and supply availability |
| Generic levofloxacin injection |
Levofloxacin |
Price-driven institutional market |
Broad substitution and formulary acceptance |
Ofloxacin’s commercial disadvantage was its weaker contemporary positioning relative to ciprofloxacin and levofloxacin. It also lacked a durable indication or delivery advantage that could justify premium pricing after generic competition matured.
What generic entry risks exist?
The principal risk from generic entry was price erosion rather than displacement of a high-revenue branded product. A generic ofloxacin injection, if commercially viable, would likely compete through:
- Group purchasing organization contracts.
- Hospital formulary placement.
- Wholesaler availability.
- Shortage response.
- Low-cost procurement for defined susceptibility patterns.
The commercial ceiling is constrained by the availability of alternative fluoroquinolones and by antimicrobial stewardship. A new entrant would need to demonstrate dependable supply and acceptable economics. Patent litigation would not be the main obstacle.
What is the financial trajectory of FLOXIN IN DEXTROSE 5%?
Product-level revenue has not been publicly reported in a sufficiently detailed form to establish a verified annual sales series. Johnson & Johnson disclosed results at broader pharmaceutical-segment levels rather than separating FLOXIN I.V. revenue in public filings [4].
The defensible financial trajectory is therefore directional:
| Period |
Financial profile |
| Launch and early adoption |
Growth supported by branded pricing and hospital use |
| Mature branded period |
Revenue supported by established formulary presence |
| Generic competition period |
Falling price and volume pressure |
| Late commercial period |
Portfolio rationalization and declining strategic value |
| Current period |
No meaningful branded growth thesis |
The product likely experienced the standard hospital anti-infective lifecycle: initial premium pricing, formulary adoption, generic erosion, lower utilization as alternatives expanded, and eventual withdrawal or commercial discontinuation.
Its economic value was also limited by the high substitution rate between intravenous and oral therapy. Patients able to tolerate oral therapy could often transition to oral ofloxacin, reducing the duration of inpatient infusion use.
What licensing deals affected FLOXIN IN DEXTROSE 5%?
No major current licensing transaction is publicly associated with FLOXIN IN DEXTROSE 5%. The product was commercialized within the Ortho-McNeil and Johnson & Johnson pharmaceutical structure rather than through a recently disclosed external licensing arrangement.
The absence of a known active licensing deal is consistent with the product’s late lifecycle. A licensee would face a mature antibiotic market, limited differentiation, no apparent patent runway, and low prospects for premium pricing.
What patent litigation affects FLOXIN IN DEXTROSE 5%?
No significant current patent litigation affects the product. The litigation profile is materially different from newer branded medicines because:
- The underlying molecule is old.
- Regulatory exclusivity has expired.
- The formulation is technically conventional.
- Public product-level sales are not substantial.
- Generic substitution is commercially available across the broader fluoroquinolone class.
Any current dispute would more likely involve manufacturing quality, supply, regulatory status, or procurement than a high-value patent contest.
What is the outlook for the competitive landscape?
The market outlook is structurally unfavorable for a branded ofloxacin intravenous product in the United States. Demand would be limited by generic competition, stewardship restrictions, alternative fluoroquinolones, and the ability to use oral therapy.
A relaunch would require a specific commercial rationale, such as:
- A prolonged shortage of competing injectable antibiotics.
- An underserved international market.
- A differentiated container or supply model.
- A government or institutional procurement contract.
- A strategic need for an additional fluoroquinolone source.
Even under those conditions, the product would be more likely to operate as a low-margin hospital injectable than as a premium branded asset.
Does FLOXIN IN DEXTROSE 5% have biosimilar risk?
No. Biosimilar risk is not applicable because ofloxacin is a chemically synthesized small molecule, not a biologic. The relevant competitive threats are generic drug applications, therapeutic substitution, formulary exclusion, and other injectable antibacterial products.
What are the geographic coverage and manufacturing barriers?
The product’s historical U.S. position does not imply current global availability. Ofloxacin products may remain marketed in selected countries, but brand names, approvals, formulations, manufacturers, and indications vary by jurisdiction.
Manufacturing barriers are moderate:
- Sterile injectable production requires qualified facilities.
- Aseptic processing and container integrity are critical.
- Stability in 5% dextrose must be validated.
- Injectable products face heightened shortage and inspection risks.
- Small market size can make dedicated production uneconomic.
These barriers may deter entry without creating durable pricing power.
Key Takeaways
- FLOXIN IN DEXTROSE 5% was an intravenous ofloxacin product in 5% dextrose for hospital use.
- Its U.S. commercial relevance is historical, not growth-oriented.
- Original regulatory exclusivity and any meaningful molecule-level patent protection have expired.
- No significant current Paragraph IV challenge or patent litigation is associated with the product.
- Biosimilar competition is irrelevant; generic and therapeutic substitution are the relevant risks.
- Ciprofloxacin and levofloxacin displaced much of the product’s competitive opportunity.
- Public filings do not provide a reliable product-specific revenue series.
- A potential relaunch would depend on supply availability, institutional contracting, or an underserved geographic market rather than patent protection.
- The principal barriers are sterile manufacturing, regulatory compliance, and limited market size.
FAQs
Is FLOXIN IN DEXTROSE 5% still sold in the United States?
The product is a legacy intravenous formulation with no meaningful active branded U.S. market position. Current availability should not be assumed from historical FDA labeling.
Is intravenous ofloxacin protected by patents?
No current patent estate appears to provide commercially meaningful protection for the legacy product. Any original composition or formulation protection would have expired.
Can a generic company launch ofloxacin injection?
Potentially, subject to the applicable FDA pathway, reference-product requirements, manufacturing controls, and commercial viability. The main challenge is limited demand rather than patent blocking.
Was FLOXIN IN DEXTROSE 5% withdrawn for safety reasons?
A commercial discontinuation does not by itself establish a safety withdrawal. Fluoroquinolone class warnings reduced use in some settings, but product discontinuation can also reflect economics, demand, supply, or portfolio decisions.
Which drug replaced FLOXIN I.V. in hospitals?
Ciprofloxacin and levofloxacin, along with their generic injectable versions, were the principal fluoroquinolone alternatives. Non-fluoroquinolone antibiotics also displaced use where stewardship or safety considerations favored other therapies.
References
-
U.S. Food and Drug Administration. (2016). FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics
-
U.S. Food and Drug Administration. (2018). FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics. https://www.fda.gov/drugs/drug-safety-and-availability/fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Johnson & Johnson. (n.d.). Annual reports and SEC filings. https://investor.jnj.com/financials/annual-reports-and-sec-filings/default.aspx
